

Toshinari Minamoto

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9177335/toshinari-minamoto-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

49
papers

1,523
citations

19
h-index

38
g-index

52
ext. papers

1,704
ext. citations

5.3
avg, IF

4.07
L-index

#	Paper	IF	Citations
49	IL-33 promotes gastric tumour growth in concert with activation and recruitment of inflammatory myeloid cells. <i>Oncotarget</i> , 2022 , 13, 785-799	3.3	0
48	Thymidylate synthase locus LOH in combination with genotype has prognostic and predictive significance in colorectal cancer. <i>Molecular and Clinical Oncology</i> , 2021 , 15, 235	1.6	
47	Coordinate expression loss of and in gastric cancer via impairment of a glucocorticoid-responsive enhancer. <i>American Journal of Physiology - Renal Physiology</i> , 2020 , 319, G175-G188	5.1	4
46	Glycogen Synthase Kinase 3 in Cancer Biology and Treatment. <i>Cells</i> , 2020 , 9,	7.9	18
45	Significance of gene mutations in the Wnt signaling pathway in traditional serrated adenomas of the colon and rectum. <i>PLoS ONE</i> , 2020 , 15, e0229262	3.7	4
44	Post-transcriptional regulation of BRG1 by FIR3on2 in gastric cancer. <i>Oncogenesis</i> , 2020 , 9, 26	6.6	6
43	Glycogen synthase kinase 3 as a potential therapeutic target in synovial sarcoma and fibrosarcoma. <i>Cancer Science</i> , 2020 , 111, 429-440	6.9	14
42	Detection and Characterization of Oncogene Mutations in Preneoplastic and Early Neoplastic Lesions. <i>Methods in Molecular Biology</i> , 2020 , 2102, 419-437	1.4	
41	Glycogen synthase kinase-3 participates in acquired resistance to gemcitabine in pancreatic cancer. <i>Cancer Science</i> , 2020 , 111, 4405-4416	6.9	3
40	Potential therapeutic effect of targeting glycogen synthase kinase 3 in esophageal squamous cell carcinoma. <i>Scientific Reports</i> , 2020 , 10, 11807	4.9	3
39	Integrated genetic and epigenetic analysis of cancer-related genes in non-ampullary duodenal adenomas and intramucosal adenocarcinomas. <i>Journal of Pathology</i> , 2020 , 252, 330-342	9.4	7
38	NF- κ B-induced NOX1 activation promotes gastric tumorigenesis through the expansion of SOX2-positive epithelial cells. <i>Oncogene</i> , 2019 , 38, 4250-4263	9.2	32
37	Anti-FIR3on2, a splicing variant form of PUF60, autoantibody is detected in the sera of esophageal squamous cell carcinoma. <i>Cancer Science</i> , 2019 , 110, 2004-2013	6.9	7
36	Identification of GSK3 inhibitor kenpaullone as a temozolomide enhancer against glioblastoma. <i>Scientific Reports</i> , 2019 , 9, 10049	4.9	14
35	Interleukin 1 Up-regulates MicroRNA 135b to Promote Inflammation-Associated Gastric Carcinogenesis in Mice. <i>Gastroenterology</i> , 2019 , 156, 1140-1155.e4	13.3	28
34	Tumor p16INK4 gene expression and prognosis in colorectal cancer. <i>Oncology Reports</i> , 2019 , 41, 1367-1375	3.5	2
33	Colorectal cancer cells require glycogen synthase kinase-3 for sustaining mitosis via translocated promoter region (TPR)-dynein interaction. <i>Oncotarget</i> , 2018 , 9, 13337-13352	3.3	14

32	High-Speed Atomic Force Microscopy Reveals Loss of Nuclear Pore Resilience as a Dying Code in Colorectal Cancer Cells. <i>ACS Nano</i> , 2017 , 11, 5567-5578	16.7	31
31	Nestin phosphorylation at threonines 315 and 1299 correlates with proliferation and metastasis of human pancreatic cancer. <i>Cancer Science</i> , 2017 , 108, 354-361	6.9	7
30	Biological basis and clinical study of glycogen synthase kinase-3β-targeted therapy by drug repositioning for glioblastoma. <i>Oncotarget</i> , 2017 , 8, 22811-22824	3.3	26
29	haplodeficiency promotes splicing to pyruvate kinase M2 in mice thymic lymphoma tissues revealed by six-plex tandem mass tag quantitative proteomic analysis. <i>Oncotarget</i> , 2017 , 8, 67955-67965	3.3	5
28	Efficacy of glycogen synthase kinase-3β-targeting against osteosarcoma via activation of β-catenin. <i>Oncotarget</i> , 2016 , 7, 77038-77051	3.3	15
27	Identification and functional analysis of an EMT-accelerating factor induced in pancreatic cancer cells by an anticancer agent. <i>Suizo</i> , 2016 , 31, 76-84	0.1	1
26	Prognostic and predictive significance of long interspersed nucleotide element-1 methylation in advanced-stage colorectal cancer. <i>BMC Cancer</i> , 2016 , 16, 945	4.8	17
25	Glycogen synthase kinase-3β is a pivotal mediator of cancer invasion and resistance to therapy. <i>Cancer Science</i> , 2016 , 107, 1363-1372	6.9	95
24	Glycogen synthase kinase 3β sustains invasion of glioblastoma via the focal adhesion kinase, Rac1, and c-Jun N-terminal kinase-mediated pathway. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 564-74	6.1	31
23	Detection and characterization of oncogene mutations in preneoplastic and early neoplastic lesions. <i>Methods in Molecular Biology</i> , 2014 , 1105, 381-98	1.4	2
22	Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling. <i>Carcinogenesis</i> , 2013 , 34, 2206-17	4.6	57
21	Aberrant glycogen synthase kinase 3β is involved in pancreatic cancer cell invasion and resistance to therapy. <i>PLoS ONE</i> , 2013 , 8, e55289	3.7	55
20	Distinct Pathologic Roles for Glycogen Synthase Kinase 3β in Colorectal Cancer Progression 2012 ,		2
19	Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine. <i>Journal of Gastroenterology</i> , 2012 , 47, 321-33	6.9	44
18	The strategy for enhancing temozolomide against malignant glioma. <i>Frontiers in Oncology</i> , 2012 , 2, 98	5.3	42
17	Aberrant glycogen synthase kinase 3β in the development of pancreatic cancer. <i>Journal of Carcinogenesis</i> , 2012 , 11, 15	1.9	10
16	The Pivotal Roles of GSK3β in Glioma Biology 2011 ,		4
15	Metabolic disorder, inflammation, and deregulated molecular pathways converging in pancreatic cancer development: implications for new therapeutic strategies. <i>Cancers</i> , 2011 , 3, 446-60	6.6	9

14	Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma. <i>Clinical Cancer Research</i> , 2009 , 15, 887-97	12.9	95
13	An emerging strategy for cancer treatment targeting aberrant glycogen synthase kinase 3 beta. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2009 , 9, 1114-22	2.2	52
12	Deregulated GSK3{beta} sustains gastrointestinal cancer cells survival by modulating human telomerase reverse transcriptase and telomerase. <i>Clinical Cancer Research</i> , 2009 , 15, 6810-9	12.9	85
11	Inhibition of GSK-3 beta activity attenuates proliferation of human colon cancer cells in rodents. <i>Cancer Science</i> , 2007 , 98, 1388-93	6.9	112
10	Detection of active fraction of glycogen synthase kinase 3beta in cancer cells by nonradioisotopic in vitro kinase assay. <i>Oncology</i> , 2006 , 71, 297-305	3.6	21
9	Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. <i>Biochemical and Biophysical Research Communications</i> , 2005 , 334, 1365-73	3.4	220
8	Detection and characterization of oncogene mutations in preneoplastic and early neoplastic lesions. <i>Methods in Molecular Biology</i> , 2005 , 291, 263-78	1.4	2
7	Oncogenic beta-catenin signaling networks in colorectal cancer. <i>Cell Cycle</i> , 2005 , 4, 1522-39	4.7	101
6	Epidermoid cyst of the intrapancreatic accessory spleen producing CA19-9. <i>Digestive Endoscopy</i> , 2004 , 16, 244-248	3.7	13
5	Detection of oncogenes in the diagnosis of cancers with active oncogenic signaling. <i>Expert Review of Molecular Diagnostics</i> , 2002 , 2, 565-75	3.8	17
4	Gene mutation as a target for early detection in cancer diagnosis. <i>Critical Reviews in Oncology/Hematology</i> , 2001 , 40, 195-213	7	11
3	Frequent and characteristic K-ras activation and absence of p53 protein accumulation in aberrant crypt foci of the colon. <i>Gastroenterology</i> , 1995 , 108, 434-40	13.3	124
2	Mutant K-ras in apparently normal mucosa of colorectal cancer patients. Its potential as a biomarker of colorectal tumorigenesis. <i>Cancer</i> , 1995 , 75, 1520-6	6.4	49
1	Renal cell carcinoma producing alpha-fetoprotein (AFP) with a unique lectins-affinity profile. <i>Journal of Surgical Oncology</i> , 1994 , 55, 215-21	2.8	10